Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Transcatheter Aortic Valve implantation (TAVi)
From the design to the procedure, the Evolut™ TAVI platform was developed to help you get your patients back to their active lifestyles.
Our valve is designed to drive favorable patient outcomes through procedural excellence and sustained hemodynamics over time.
Specifically developed to enhance procedural consistency, the cusp overlap technique facilitates implant depth accuracy1 and predictable valve deployment. Additional procedural techniques such as flush port at 3 o'clock help to achieve commissural alignment that may facilitate future coronary access.2
Future coronary access is feasible with the Evolut platform. See how you can keep future treatment options open by leveraging the design of the valve frame and following our procedural techniques.2
The Evolut TAVI platform is built on the original CoreValve™ platform, which pioneered the design elements that enable excellent hemodynamic performance. See how we designed for durability.
TAVI risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker.
Grubb KJ. An Optimized TAVR Care Pathway Using Evolut PRO and PRO+ Early Results From the Optimize PRO Study. Presented at SCAI Virtual Scientific Sessions; April 28-May 1, 2021.
Tang GHL, Zaid S, Fuchs A, et al. Alignment of Transcatheter Aortic-Valve Neo-Commissures (ALIGN TAVR): Impact on Final Valve Orientation and Coronary Artery Overlap. JACC Cardiovasc Interv. May 11, 2020;13(9):1030–1042.